Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Medical Devices & Diagnostics

GHO Capital and CBC Group deal signals a bigger private capital push into life sciences

GHO Capital and CBC Group are creating a $21bn healthcare investor. Find out what it means for pharma, medtech and life sciences funding.

Read More
Pharma & Biotech

Coya Therapeutics advances COYA 302 as FDA fast track status raises clinical expectations

Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.

Read More
Pharma & Biotech

Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?

Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.

Read More
Representative image: Scientists work inside an advanced iPSC biomanufacturing lab as FUJIFILM Cellular Dynamics’ Madison facility highlights growing demand for stem cell manufacturing, regenerative medicine infrastructure and cell therapy scale-up.
Pharma & Biotech

Can FUJIFILM’s Madison facility help solve the scale problem in stem cell manufacturing?

iPSC demand is rising fast. FUJIFILM’s Madison facility tests whether stem cell manufacturing can keep pace with pharma and cell therapy needs.

Read More
Representative image: Scientists review DNA delivery and lipid nanoparticle research in a genetic medicines lab as Eli Lilly’s Engage Bio acquisition highlights the growing race to solve non-viral drug delivery challenges.
Pharma & Biotech

Eli Lilly expands genetic medicines toolkit with Engage Bio’s non-viral DNA delivery system

Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.

Read More
Representative image: Healthcare workers review treatment supplies in a regional clinic as Gilead Sciences and the World Health Organization renew efforts to expand AmBisome access and strengthen visceral leishmaniasis elimination programmes.
Pharma & Biotech

Why Gilead’s visceral leishmaniasis collaboration with WHO matters beyond drug donation

Gilead’s WHO pact targets kala-azar access, but diagnostics, treatment delivery and East Africa execution will decide the impact.

Read More
Representative image: Researchers review AI-enabled virtual screening data and molecular models in a drug discovery lab as Concept Life Sciences and OpenBench push a success-based model for faster, lower-risk biotech hit validation.
Pharma & Biotech

Concept Life Sciences expands drug discovery model as OpenBench brings AI-enabled screening scale

Biotechs need faster hits with less upfront risk. Concept Life Sciences and OpenBench are testing whether success-based discovery can deliver.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More
Representative image: A laboratory professional reviews STI test samples and public health data as Europe’s record rise in gonorrhoea, syphilis and chlamydia cases puts diagnostics, prevention and antimicrobial resistance strategies under renewed scrutiny.
Medical Devices & Diagnostics

Can Europe contain its STI surge before antimicrobial resistance narrows treatment options?

Europe’s STI surge is testing diagnostics, prevention and treatment capacity as gonorrhoea and syphilis reach record levels.

Read More
Pharma & Biotech

Why Recordati’s $12.4bn takeover bid could reshape Italy’s listed pharma landscape

Recordati’s $12.4bn buyout bid tests whether rare disease growth can justify one of Europe’s biggest pharma take-private deals.

Read More